Venlafaxine deprescribing and thyroid function
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-06 · 43 (6) · 570-573
DOI: 10.1002/phar.2803 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 26.04.2023. Verfasst von Barbara J Zarowitz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Deprescriptions, Hashimoto Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Study Objective This report highlights the effects of discontinuing venlafaxine on thyroid function in an older adult with previously well‐managed Hashimoto thyroiditis and sleep apnea.
Design
Concurrent intervention. Case study.
Setting
Community‐based psychiatry practice Patient ‐ 66 year old female Intervention Over 8 months, a 66‐year‐old patient slowly reduced the venlafaxine dose. She was treated simultaneously for sleep apnea.
Measurements
Clinical data including venlafaxine and levothyroxine dosing, thyroid hormone laboratory values, subjective complaints, and objective electrocardiographic (ECG) findings were aggregated and analyzed. Main Results As venlafaxine dose was decreased over time, the patient complained of bounding heart palpitations shown to be premature ventricular contractions, and wide and narrow complex ventricular tachycardia on ECG. Thyroid‐stimulating hormone decreased from a baseline value of 0.791 uIU/mL to a nadir of 0.18 uIU/mL during venlafaxine dosage reduction from 225 mg/day to 155 mg/day. Cardiac symptoms subsided following levothyroxine dosage reduction.
Conclusions
There was a direct relationship between antidepressant dosage reduction and levothyroxine dosage requirements. Cautious monitoring is recommended during venlafaxine deprescribing in patients with pre‐existing thyroid disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
- Cairn Center, Las Vegas, Nevada, USA.
ORCID-Profile: Barbara J Zarowitz
Zitieren
APA
Zarowitz, B. J., & Jain, S. (2023). Venlafaxine deprescribing and thyroid function. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(6), 570-573. https://doi.org/10.1002/phar.2803
Vancouver
Zarowitz BJ, Jain S. Venlafaxine deprescribing and thyroid function. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(6):570-573. doi:10.1002/phar.2803
BibTeX
@article{Zarowitz2023,
author = {Zarowitz, Barbara J and Jain, Shaily},
title = {Venlafaxine deprescribing and thyroid function},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
volume = {43},
number = {6},
pages = {570--573},
doi = {10.1002/phar.2803}
}
EUVIMED